secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sagimet Biosciences Inc. (SGMT)
CIK:        0001400118
Form:       8-K
Filed at:   2024-08-14T23:59:59+00:00
Accession:  0001104659-24-089340
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sagimet Q2 net loss $8.1M, cash $188.5M; denifanstat fibrosis data positive; Phase 3 plan H2 2024
--------------------------------------------------------------------------------

- Cash and marketable securities $188.5M as of June 30, 2024; net loss $8.1M for Q2 2024 vs $6.8M year ago.
- Denifanstat Phase 2b: fibrosis improvement ≥1 stage in 30% vs 14% placebo (ITT); 49% vs 13% in F3 patients.
- Anne Phillips and Jennifer Jarrett appointed to board effective August 1, 2024.
- Phase 3 program for denifanstat in MASH expected to start H2 2024; CRO contract executed.
- R&D expense $6.3M and G&A $4.3M in Q2 2024, up from $4.7M and $2.4M year ago.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1400118/000110465924089340/0001104659-24-089340-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1400118/000110465924089340/tm2421625d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-089340

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer